Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Frontier Says HIV Therapy Effective in Difficult-to-Treat Patients

publication date: Jul 19, 2021

Nanjing Frontier Biotech announced positive top-line results from a China Phase III trial of its long-acting two-drug therapy for AIDS. In the trial, Frontier's once-weekly Aikening® (albuvirtide) plus lopinavir (LPV) showed it was not inferior to a lopinavir three-drug arm in an Asian population that had failed initial treatment. Two NRTIs were replaced with Aikening® in the combination therapy, which produced rapid and persistent viral suppression. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital